All News

    Primary Central Nervous System Lymphoma Patient and Care Partner Roundtable Hosted by the End Brain Cancer Initiative

    March 3rd 2025, 6:33pm

    Article

    Accepting My Colon Cancer Diagnosis at A Young Age

    March 3rd 2025, 6:00pm

    Article

    Being diagnosed with colon cancer at 34 was difficult, but choosing happiness and acceptance helped me find peace through mindfulness, nature and family.

    Rusfertide Elicits Promising Responses in Polycythemia Vera

    March 3rd 2025, 5:00pm

    Article

    Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.

    FDA Accepts Ordspono Resubmission in R/R Follicular Lymphoma Treatment

    March 3rd 2025, 4:00pm

    Article

    The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

    My Journey With Squamous Cell Carcinoma

    March 3rd 2025, 2:00pm

    Article

    A patient shares his experience with a squamous cell carcinoma diagnosis, treatment and recovery.

    First Patient With Small Cell Lung Cancer Dosed With Peluntamig

    March 2nd 2025, 7:00pm

    Article

    The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

    First Patient Dosed With HLD-0915 for mCRPC in First-In-Human Trial

    March 2nd 2025, 3:00pm

    Article

    The first patient has been dosed in a first-in-human clinical trial evaluating HLD-0915 for metastatic castration-resistant prostate cancer.

    Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma

    March 1st 2025, 7:00pm

    Video

    Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.

    Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer

    March 1st 2025, 3:00pm

    Article

    Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer.

    Cema-Cel Has Durable Responses in in Relapsed/Refractory Large B-Cell Lymphoma

    February 28th 2025, 10:00pm

    Article

    Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.